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Abstract
Introduction: Interleukin (IL)-21 is a cytokine that controls the functional activity of effector T helper cells and the
differentiation of Th17 cells, and promotes B-cell differentiation. To test whether IL-21 participates in the
pathogenesis of primary Sjögren’s syndrome (SS), serum IL-21 level was measured and IL-21 expression in the labial
salivary glands (LSG) was examined.
Methods: Serum IL-21 levels in 40 primary SS, 40 rheumatoid arthritis (RA), and 38 systemic lupus erythematosus
(SLE) patients and 20 healthy controls were measured. Serum IL-21 levels of SS patients were assessed for
correlations with laboratory data, including anti-nuclear antibody, anti-Ro/La antibodies, globulin, immunoglobulin
(Ig) class, and IgG subclass. LSGs from 16 primary SS and 4 controls with sicca symptoms were evaluated for IL-21
and IL-21 receptor (IL-21R) expression by immunohistochemistry. Confocal microscopy was performed to further
characterize the IL-21 positive cells.
Results: Primary SS patients had significantly higher serum IL-21 levels than controls, and these increments
correlated positively with levels of IgG, IgG1. Serum IgG1 levels correlated with anti-Ro antibody titers.
Immunohistochemical analyses showed that lymphocytic foci and the periductal area of the LSGs from SS patients
expressed high levels of IL-21 and lower levels of IL-21R, whereas the control LSGs showed minimal expression of
both antigens. The more the lymphocyte infiltrated, IL-21expression in LSGs showed a tendency to increase.
Confocal microscopic analyses revealed that IL-21 expressing infiltrating lymphocytes in the LSGs of SS patients
also expressed CXCR5.
Conclusions: Primary SS is associated with high serum IL-21 levels that correlate positively with serum IgG,
especially IgG1, levels. The expression of IL-21 is increased as more lymphocytes infiltrated in LSGs. These
observations suggest that IL-21 may play an important role in primary SS pathogenesis.
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IL-21 is a pleiotropic cytokine that belongs to the com-
mon cytokine receptor g chain (gc)-dependent cytokine
family, which is produced by activated CD4+ T cells
and NKT cells [1]. The IL-21 receptor (IL-21R) consists
of the IL-21R a chain and the gc chain and is expressed
on T cells, NK cells, NKT cells, B cells, dendritic cells
(DCs) and macrophages as well as on non-hematopoie-
tic cells, including keratinocytes and fibroblasts [2]. The
activation of IL-21R by the binding of IL-21 enhances
the proliferation of T cells after their prior stimulation
with anti-CD3 [3]. IL-21 also controls the functional
activity of effector T helper (Th) cells and the differen-
tiation of Th17 cells, and counteracts the suppressive
effects of regulatory T cells [4]. IL-21 alone is capable of
directly inducing both B lymphocyte-induced maturation
protein-1 (Blimp-1), which is required for plasma-cell
differentiation, and Bcl-6, which is required for germinal
center reactions [5]. IL-21 also promotes B-cell differen-
tiation by synergizing with BAFF and enhancing the
CD40-mediated induction of activation-induced deami-
nase (AID) and Blimp1 [6]. Overexpression of IL-21 in
mice results in hypergammaglobulinemia and autoanti-
body production [7].
Primary Sjögren’s syndrome (SS) is a systemic autoim-
mune disease characterized by keratoconjunctivitis sicca,
xerostomia, and extraglandular abnormalities [8]. At the
immunological level, it is characterized by both T-cell
lymphocytic infiltration of the exocrine glands and B-cell
hyper-reactivity. Hypergammaglobulinemia is a common
laboratory finding in primary SS. Since previous observa-
tions suggest that IL-21 and IL-21R may be associated
with immunoglobulin production, autoantibody produc-
tion, and B-lymphocyte hyperactivity [3,9], it is thought
that IL-21 is involved in the pathogenesis of autoimmune
disease. However, the precise roles IL-21 and IL-21R in
human autoimmune disease are still poorly understood.
To determine whether IL-21 participates in primary SS
pathogenesis, we examined whether the serum IL-21
levels of patients with primary SS correlate with various
laboratory parameters. The expression of the IL-21/IL-
21R cytokine/receptor pair by the salivary glands of
patients with primary SS was also investigated.
Materials and methods
Patients and samples
The participants were selected from patients at Seoul Saint
Mary’s hospital at the Catholic University of Korea. Writ-
ten informed consent was obtained from all patients and
controls. The study was approved by the ethical commit-
tee of the Seoul St. Mary’s Hospital (KC09FZZZ0522). For
serological studies, serum samples were obtained from 40
patients with primary SS, 38 patients with systemic lupus
erythematosus (SLE), 40 patients with rheumatoid arthritis
(RA), and 20 healthy controls. All SLE and RA patients
fulfilled American College of Rheumatology (ACR) classifi-
cation criteria [10,11]. The consent form was approved by
the Hospital Ethics Committee. In addition, labial salivary
gland (LSG) biopsy specimens were collected from 16
patients (all women) that matched the histological criteria
for a diagnosis of SS [12] and had severe cellular infiltra-
tion (focus score ≥1). All patients were female. The mean
age and the duration of disease were 51.7 ± 9.5 years and
0.3 ± 1.0 years. The biopsies were performed for routine
diagnostic purposes after obtaining the patient’sc o n s e n t .
All patients diagnosed with primary SS fulfilled the Ameri-
can-European Consensus Group Criteria for this diagnosis
[13]. There were also four control LSG specimens from
subjects who did not fulfill the classification criteria for
primary SS but had sicca symptoms, such as dry mouth or
dry eyes. The controls were matched for sex and age to
the primary SS patients and had been examined for the
presence of rheumatic disease, including secondary SS.
Clinical and immunological data
All patients underwent extensive medical examinations
and serological evaluations, including measurements of
anti-nuclear antibody (ANA), rheumatoid factor (RF),
globulins and Ig classes, along with the erythrocyte sedi-
mentation rate (ESR). In addition, the anti-Ro/SSA, anti-
La/SSB, and IgG subclass titers in primary SS patients
were measured.
The anti-Ro/SSA and anti-La/SSB antibodies were
tested by using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (BIO QUANT, San
Diego, CA and USA). To measure IgG1, IgG2, IgG3 and
IgG4 titers, a Human IgG Subclass Profile ELISA kit
(Invitrogen, Camarillo, CA, USA) was used.
Labial salivary gland biopsy
LSG biopsies were taken from primary SS patients at an
otorhinolaryngology clinic. For this, local anesthetic was
injected into the lower lip and a small incision to the
right or left of the lip midline was made. Five or six
LSG lobules were harvested carefully and placed into
10% phosphate-buffered formalin for 24 hours. Standard
paraffin preparations were prepared, sectioned at a
thickness of 5 μm, and stained with hematoxylin and
e o s i n .T h es l i d e sw e r ee x a m i n e df o rt h ep r e s e n c eo f
lymphocytic infiltrates and/or foci by three observers
using standardized criteria. The focus score was
reported as the number of foci per 4 mm
2 of tissue.
Measurement of serum IL-21
The IL-21 concentrations in the sera from the 40 pri-
mary SS patients, 38 SLE patients, 40 RA patients, and
20 healthy controls were measured by sandwich ELISA.
Briefly, monoclonal capture antibodies (eBioscience, San
Kang et al. Arthritis Research & Therapy 2011, 13:R179
http://arthritis-research.com/content/13/5/R179
Page 2 of 10D i e g o ,C Aa n dU S A )w e r ea d d e dt oa9 6 - w e l lp l a t e
(Nunc) and incubated overnight at 4°C, after which the
plates were washed five times with PBS containing
0.05% Tween20. Following incubation with blocking
solution for one hour at room temperature, the test
samples and recombinant IL-21 (eBioscience) standards
were added to the plates. The plates were incubated for
two hours at room temperature, after which they were
washed five times. Biotin-conjugated anti-human IL-21
antibodies (eBioscience) were added and, incubated for
an hour at room temperature and the plates were
washed. Avidin-horseradish peroxidase (eBioscience)
was added and the reaction was allowed to proceed for
30 minutes at room temperature. The plates were then
washed five times, and TMB solution was added to
induce the color reaction, which was stopped by adding
2N H2SO4. The optical density at 450 nm was measured
by using an automated microplate reader (VERSAmax,
Molecular Devices, Palo Alto, CA, USA). A standard
curve was drawn by plotting the optical density against
the log of the concentration of IL-21.
Immunohistochemical staining for IL-21 and IL-21R
The fixed LSG biopsy specimen slides were deparaffi-
nized by immersion in xylene, followed by dehydration in
ethanol. The sections were incubated for 30 minutes at
room temperature with blocking solution containing nor-
mal sera and avidin block (Vector Laboratories, Burlin-
game, CA, USA), and then incubated overnight at 4°C
with either anti-IL-21 (Santa Cruz Technology Inc.,
Santa Cruz, CA, USA) or anti-IL-21R, both of which
were diluted 1:100 (R&D Systems, Minneapolis, MN and
USA). Mouse IgG or goat IgG served as isotype controls.
The slides were washed for 5 minutes, followed by a 20-
minute incubation with biotinylated anti-rabbit IgG or
biotinylated anti-goat IgG (Vector). Following a 15-min-
ute wash, the slides were incubated for 1 h with horse-
radish peroxidase-conjugated avidin-biotin by using the
Vectastain ABC Elite (Vector). The stain was developed
by using diaminobenzidine substrate (DAKO, Carpin-
teria, CA, USA). Counterstaining was performed with
hematoxylin. Enumeration of IL-21-positive cells was
performed in the vicinity of LSG lymphocytic infiltration
and in the interstitium. One lymphocytic focus per speci-
men was randomly selected for enumerating the number
of positively stained cells. Quantification of IL-21-positive
cells was performed with the HistoQuest analysis soft-
ware (TissueGnostics, Los Angeles, CA and USA).
Confocal microscopic analysis of LSG co-expression of
CD4, CD20, CXCR5, and IL-21
Salivary gland pieces from eight patients were analyzed.
Cryosections (7-μm thick) were fixed with acetone,
blocked with 10% goat serum, and stained with anti-
CD4-FITC, anti-CD20-FITC (BD Biosciences, Franklin
Lakes, NJ and USA), anti-CXCR5-PerCP-Cy5.5 (Biole-
gend, San Diego, CA and USA), and anti-IL-21-PE
(eBioscience). Fluorescence images were acquired by
using a LSM 510 confocal microscope (Zeiss, Berlin,
Brandenburg and Germany).
Statistical analysis
Statistical analyses were performed by using SAS soft-
ware (Version 9) (Cary, North Carolina and USA). The
data were expressed as individual values with median.
Differences in the mean IL-21 levels of various groups
were analyzed by using the Kruskal-Wallis test. Differ-
ences between the two groups were analyzed by using
the Mann-Whitney test (two-tailed). Spearman’sr a n k
test was used to assess the correlation between the
levels of IL-21 and laboratory data. Values of P <0 . 0 5
were considered significant.
Results
Primary SS patients have higher serum IL-21 levels than
healthy controls
Measurement of the serum IL-21 levels in primary SS (n
= 40), SLE (n =3 8 ) ,a n dR A( n = 40) patients and
healthy controls (n = 20) by ELISA revealed mean IL-21
levels of 646 ± 637, 454 ± 534, 342 ± 322, and 74 ± 132
pg/ml, respectively (Figure 1). The serum IL-21 levels
varied significantly among patients with primary SS,
SLE, RA and controls (P < 0.01). The levels of primary
Figure 1 The serum IL-21 level. The serum IL-21 levels of patients
with primary SS (n = 40), SLE (n = 38), or RA (n = 40) and healthy
controls (n = 20) were measured by ELISA. The primary SS patients
had significantly higher serum IL-21 levels than the healthy controls
or the RA patients. Horizontal bars represent the median of all
samples within a group. * P < 0.05, ** P < 0.01. IL: Interleukin; RA:
rheumatoid arthritis; SLE: systemic lupus erythematosus; SS: Sjögren’s
syndrome.
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0.01). The primary SS group also had higher IL-21 levels
than the RA group (P < 0.05) but did not differ signifi-
cantly from the SLE group.
The serum IL-21 levels in patients with primary SS
correlate with their globulin, IgG, and IgG1 levels
To identify possible correlations between serum IL-21
levels and laboratory data of primary SS, the clinical
data of the 40 primary SS patients were examined. The
patients had normal clinical test results, except for the
tests measuring the levels of ANA, anti-Ro/SSA, anti-
La/SSB, RF, globulin, and the ESR. The serum IL-21
levels of the patients did not correlate with ANA or RF
titers or ESR, but did correlate with globulin and IgG
levels (globulin: g = 0.482, P = 0.002; IgG: g = 0.438, P =
0.009). The regression lines for these correlations are
shown by the lines in Figures 2a, b. On the other hand,
the IL-21 levels did not correlate significantly with other
Ig classes. Among IgG subclasses, only the IgG1 levels
correlated significantly with IL-21 levels (r = 0.463, P =
0.023), as shown in Figure 2c. Figure 2d shows that the
IgG1 levels also correlated with the anti-Ro/SSA anti-
body titers (r = 0.444, P = 0.007). IL-21 also correlated
with anti-Ro/SSA antibody titers (Figure 2e) and IL-21
was an independent variable explaining the anti-Ro/SSA
antibody in regression analysis, as shown in Table 1 (r =
0.501, P = 0.006). The patients with and without extra-
glandular manifestations did not differ significantly in
terms of serum IL-21 levels (data not shown).
Expression of IL-21 and IL-21R in LSGs from patients with
primary SS
Immunohistochemical analyses were performed to
determine whether IL-21 and IL-21R are expressed by
the LSGs of 16 primary SS patients and 4 healthy con-
trols. The freshly explantedl o w e rl i pb i o p s ys p e c i m e n s
were sectioned and stained with anti-IL-21 and anti-IL-
21R antibodies. All 16 primary SS samples exhibited dis-
tinct expression of IL-21 (Figure 3a), while 14 of the 16
samples were positive for IL-21R (Figure 3b). In con-
trast, none of the LSGs from the healthy controls exhib-
ited IL-21 and IL-21R expression (Figure 4). The 14
primary SS patients stained for IL-21R showed similar
patterns of IL-21 and IL-21R expression; that is, IL-21
was prominent in infiltrating lymphocytes and ductal
cells, while IL-21R was mainly expressed on ductal cells.
A weak expression of IL-21R was also observed in lym-
phocytic infiltrates. Staining of both IL-21 and IL-21R
appeared as a diffuse pattern. Overall, the expression of
IL-21 was stronger and more widely distributed than IL-
21R. Both IL-21 and IL-21R were expressed on lympho-
cytic infiltrates and to a lesser degree in the acinar com-
ponents (Figure 3).
Immunohistochemical analysis of IL-21 and IL-21R
The primary SS patients were divided according to their
grade of lymphocytic infiltration (grades 1 to 4;
described in the Methods). A grade 2 specimen is
shown in Figure 4a; this specimen was obtained from a
primary SS patient who fulfilled the American-European
Consensus Group Criteria, except LSG biopsy. Moderate
lymphocytic infiltration was observed but a definite lym-
phocytic focus was not seen. The specimens that had
grade 3 or 4 had one or more foci. IL-21 positive cell
number was increased more in both grade 3 and grade
4t h a ni nt h ec o n t r o l ,a ss h o w ni nF i g u r e4 d .T h o u g h
there are no significant differences between grade 3 and
grade 4, the more severe the lymphocytic infiltration
was, the more IL-21 was expressed on both the infiltrat-
ing lymphocytes and periductal area (Figure 4e). How-
ever, we could not show a significant relationship
between IL-21R positive cell number and the severity of
lymphocytic infiltration.
Co-expression of IL-21 and CXCR5 in the LSGs of patients
with primary SS
Earlier studies have reported that the LSGs of primary
SS patients can have a germinal center-like structure
that is composed of follicular helper T cells (TfH), B
cells and DCs [14,15]. It is also known that TfH cells
produce IL-21, which promotes the expression of the
TfH marker CXCR5 [16]. We investigated whether LSG
expression of IL-21 corresponds to its CXCR5 expres-
sion. Indeed, confocal microscopy revealed that the IL-
21 expression of LSGs from primary SS patients coin-
cided with their CXCR5 expression (Figure 5a). Since B
cells are also known to express CXCR5 [17], we assessed
whether IL-21 co-expressed with B cells as well. How-
ever, IL-21 expression did not merge with the expres-
sion of CD20, a B-cell marker (Figure 5c).
Discussion
In this study, we assessed the expression pattern of IL-
21 and IL-21R in LSG tissues of primary SS patients.
Our results encouraged the original observation demon-
strating the correlation between IL-21 expression and
IgG levels in association with disease severity of SS.
The role of IL-21 in the pathogenesis of SS is poorly
understood, but several lines of thought support the
notion that it may contribute to a pivotal role in the
process of disease. First, it is known that IL-21 is
involved in the proliferation and survival of B cells, pro-
moting their differentiation into Ig-producing plasma
cells [1]. The latter ability of IL-21 [7,18] suggests that
this cytokine may play important roles in B cell-
mediated autoimmune diseases and allergies. Second,
n a ï v eI L - 2 1 RK Om i c eh a v ed i m i n i s h e ds e r u mI g G 1
levels and immunization of these mice with T-
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Page 4 of 10Figure 2 Correlations between the serum IL-21 levels of primary SS patients and the levels of immunoglobulin. (a) The serum IL-21
levels of primary SS patients (n = 40) correlated significantly with the serum globulin levels. (b) Of all the Ig classes, the serum IL-21 levels only
correlated with IgG (n = 40). (c) There was a positive correlation between the serum IL-21 and IgG1 levels (n = 24). (d) The anti-Ro/SSA antibody
titers, as measured by ELISA, correlated with the IgG1 levels (n = 35). (e) The serum IL-21 levels correlated with anti-Ro/SSA antibody index (n =
24) and IL-21 was an independent variable in regression analysis. The correlation coefficients (r) and P-alues of statistical significance are shown.
IG: immunoglobulin; IL: Interleukin; SS: Sjögren’s syndrome.
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levels compared to wild-type mice [3]. Third, SS patients
have increased IgG levels in their serum, although the rea-
son for this increment has not been explained. The B-cell
infiltration in the LSGs from primary SS patients is less
than the T-cell infiltration; however, B-cell hyperactivity is
an important characteristic of primary SS. Indeed, a pro-
minent humoral autoimmune response in patients with
primary SS is the production of anti-Ro/SSA antibodies.
Moreover, with regard to the IgG subclasses of the anti-Ro
antibodies, IgG1 predominates [19]. In this study, we
found that the serum IL-21 levels correlated with the
serum globulin, IgG, and, in particular, IgG1 levels in pri-
mary SS patients. These observations are consistent with
Table 1 Multivariate regression analysis between IL-21,
IgG1 and Anti-Ro Antibody
Anti-Ro antibody
B SE* 95% CI P-value
Constant 1.709 0.236 1.218 to 2.200 0.000
IL-21 (pg/ml) 0.001 0.000 0.000 to 0.001 0.014
IgG1 (ug/ml) 0.013 0.004 0.004 to 0.022 0.008
*SE: standard error.
CI: confidence interval; Ig: immunoglobin; IL: interleukin.
Figure 3 The labial salivary glands (LSG) of primary SS exhibit
increased IL-21 and IL-21 receptor expression. Shown is the
expression of the IL-21 and IL-21 receptor in the labial salivary
glands of control subjects (n = 4; upper panel) and patients with
primary SS (n = 16; lower two panels), as determined by
immunostaining using specific antibodies. The cells that stained
with the antibodies appeared in brown. (a) The infiltrating
lymphocytes and periductal areas of the patients with SS exhibited
intense IL-21 staining, whereas there was no staining with the
isotype controls. (b) The lymphocytic infiltrations and periductal
areas stained for IL-21 receptor. In contrast, the control subjects did
not exhibit any IL-21 or IL-21 receptor expression in their labial
salivary glands. IL: Interleukin; LSGs: labial salivary glands; SS:
Sjögren’s syndrome.
Figure 4 The expression of IL-21 in the LSG of SS patients and
the severity of inflammation. The labial salivary gland specimens
of the primary SS patients were divided according to the grade (1
to 4) of lymphocytic infiltration (see Methods). (a) This specimen
was obtained from a SS patient who fulfilled the American-
European Consensus Group Criteria except LSG biopsy. There were
no definite lymphocytic foci but moderate lymphocytic infiltration
was observed. (a-c) IL-21 expression increased as the lymphocytic
infiltration in the salivary gland became more severe. (d) IL-21
positive cell number was significantly increased in LSG from SS
patients than in control. (e) Relationship between IL-21 positive cell
number and inflammation severity. IL-21 positive cell number was
elavated with grade (r = 0.521, P = 0.038). Horizontal bars represent
the median of all samples within a group. Representative data are
shown. IL-21: Interleukin-21; LSGs: labial salivary glands; SS: Sjögren’s
syndrome.
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addition, we found the IgG1 levels correlated with the
serum anti-Ro/SSA antibody titers. Thus, our observations
support the notion that IL-21 may promote autoantibody
production by inducing IgG class switch recombination in
B cells.
IL-21 regulates the activation, proliferation and survi-
v a lo fC D 4 +Tc e l l sa sw e l la st h a to fBc e l l s[ 2 0 , 2 1 ] .
Specifically, it up-regulates the expression of the ROR gt
transcription factor, promotes Th17-cell differentiation,
and induces IL-23R expression on Th17 cells, thus facil-
itating the ability of IL-23 to expand the Th17-cell
response [22,23]. IL-21 also regulates the functional
activity of CD8+ T cells and NK cells [20,21]. Naive
CD8+ T cells express low levels of IL-21R [24] and,
although IL-21 does not by itself induce CD8+ T-cell
proliferation, it acts synergistically with IL-15 or IL-7 to
induce the proliferation of both naïve and memory phe-
notype CD8+ T cells [25].
Our study showed that IL-21 correlates with the
degree of lymphocytic infiltration in the LSGs of
patients with primary SS. The lymphocytic foci and peri-
ductal areas of the LSGs had many IL-21 and IL-21R
positive cells. In contrast, the LSGs of healthy control
subjects did not express IL-21 or IL-21R. Together these
data suggest that IL-21 and IL-21Rpositive cells may
play an important role in the sialoadenitis suffered by
patients with primary SS.
Figure 5 Confocal microscopic analysis of the IL-21-expressing cells in the LSGs of primary SS patients. (a) Immunofluorescent double-
staining of IL-21-expressing cells (red) and CXCR5+ cells (blue). (b) Immunofluorescent double-staining of CD4+ T cells (green) and CXCR5+ cells
(blue). (c) Immunofluorescent double-staining of IL-21-expressing cells (red) and CD20+ B cells (green). Only the IL-21-expressing cells merged
with the CXCR5+ cells. IL-21: Interleukin-21; LSGs: labial salivary glands; SS: Sjögren’s syndrome.
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have elevated IL-21 levels suggested that IL-21 may play
ar o l ei na u t o i m m u n i t y .H e r b e ret al.s h o w e dt h a t ,i n
the MRL-Fas
lpr mouse model of SLE, blocking IL-21
with IL-21R-Fc reduced renal disease lymphadenopathy,
skin lesions, and circulating autoantibodies and IgG
[26]. Similarly, administra t i o no fa nI L - 2 1 R - F cf u s i o n
protein to BXSB.B6-Yaa+/J mice, the second SLE animal
model, decreased IL-21 production, lymphocyte activa-
tion and circulating IgG1 levels [27]. These data are in
agreement with the results from our study, suggesting
the notion that IL-21 may participate in autoimmune
disease pathogenesis by influencing lymphocytic activa-
tion and IgG production. Further supporting this possi-
bility is that the blockade of endogenous IL-21 activity
by an IL-21R-Fc fusion protein in the cultured RA syno-
vial membrane cells significantly inhibited the produc-
tion of inflammatory cytokines [28]. Moreover,
administration of IL-21R-Fc to collagen-induced arthritis
mice and adjuvant-induced arthritis rats alleviated their
clinical and histological signs of inflammation [9].
Additional lines of evidence also suggest that IL-21
may promote human autoimmune disease in general.
Yuan et al. have reported that patients with SS have
higher serum IL-21 levels than healthy control subjects,
which correlated positively with gamma-globulin levels
[29]. Moreover, by using a large sample of SLE patients
and healthy controls, Sawalha et al.f o u n dt h a tS L Ei s
associated with two single nucleotide polymorphisms of
the IL-21 gene [30]. In addition, patients with SLE have
elevated IL-21 serum levels that correlate with the sever-
ity of the disease [31]. Similarly, Astrid et al.h a v e
reported that synovial fibroblasts and synovial macro-
phages of patients with RA express IL-21R (IL-21 was
not tested) [32]. In addition, the epidermis of patients
with systemic sclerosis expressed IL-21R (but not IL-21)
[33]. Recently, genome-wide association studies have
provided convincing evidence that the chromosomal 4g
27 region that harbors the IL-21 and IL-21 genes is
associated with chronic inflammatory disorders, includ-
ing SLE, inflammatory bowel disease and psoriasis
[30,34,35].
Interestingly, two previous studies reported that they
were not able to detect IL-21 in the synovium of RA
patients or the skin of systemic sclerosis patients
[32,33]. This may relate to an observation made in the
experimental autoimmune encephalitis (EAE) animal
model; while the treatment of mice with IL-21 after
EAE was induced did not affect the severity of the dis-
ease, treatment before disease induction greatly
enhanced the inflammatory influx into the central ner-
vous system and the severity of the disease [36]. The lat-
ter mice also exhibited higher levels of circulating
myelin-specific antibodies and IFN-g, but the level of IL-
4 remained similar to that of control mice. Thus, the
effects of IL-21 may be specific to the early stages of the
autoimmune response. We found what may support this
hypothesis. When we measured the serum levels of
proinflammatory cytokines, such as IL-6, IL-17 and IL-
23, to determine whether serum IL-21 expression corre-
lates with systemic inflammation, we failed to detect any
significant correlations (data not shown). Thus, it is pos-
sible that IL-21 is involved at the onset of autoimmune
disease rather than later during the active systemic
inflammation stage. In the present study, the LSG biop-
sies were performed for diagnostic purposes, thus the
biopsy specimens are likely to be tissues from the early
phase of primary SS. Since we found that IL-21 and IL-
21R are expressed in these LSGs, it may be that IL-21
plays an important role in the onset and early develop-
ment of primary SS.
Our data showed that IL-21 expression was prominent
in infiltrating lymphocytes and ductal cells. It is not yet
known whether the epithelial cells lining the duct pro-
duce IL-21. Therefore, we could not completely exclude
the possibility that the high expression of IL-21 in the
ductal cell is the specificity of the reagents or the arti-
fact in the staining procedure. However, it is known
that IL-21 is expressed in non-immune cells as well as
in lymphocyte. IL-21 expression is enhanced at the site
of the involved gut in Crohn’s disease [37]. IL-21 is also
expressed in neurons in the gray matter in multiple
sclerosis [38]. This suggested the possibility that IL-21
can be produced in non-immune cells, including epithe-
lial cells.
The glandular destruction in SS has been shown to be
mediated mainly by primed CD4+ T cells [39]. Of the
lymphocytes that infiltrate the salivary glands in patients
with SS, 45 to 50% are CD4+ T cells, 20% are CD8+ T
cells, and about 20% are B cells [40]. Interestingly, the
confocal microscopic analyses in the present study
revealed that the LSG-infiltrating cells that stained for
IL-21 also stained for CXCR5. CXCR5 is a chemokine
receptor that is expressed by all mature B cells as well
as by a subset of antigen-experienced CD4+ T cells in
lymphoid tissue [41]. CXCR5 is strongly implicated in
the follicular migration of early-activated T cells and
their consequent co-localization with B cells [42]. The
priming of CD4+ T cells in lymphoid tissue result in
their novel expression of CXCR5 [43,44]. However,
CXCR5 is rapidly lost during T-cell proliferation, which
indicates that the follicular homing program is an early
and transient stage in the T-cell activation and differen-
tiation process [44,45]. Continued CXCR5 expression
after priming may reflect qualitative or quantitative
aspects of this stimulation [46]. Since the majority of
the T cells in the salivary glands of primary SS patients
are CD4+ T cells, and the IL-21 produced by activated
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of CXCR5 [16], IL-21 possibly promotes the co-localiza-
tion of T cells and B cells in the functional ectopic
germinal centers in the salivary glands of SS patients,
which in turn elevates autoantibody production. Taken
together, these observations suggest that high expression
of IL-21 may play an important role in the pathogenesis
of primary SS by affecting both T cells and B cells.
Conclusions
O u rp r e s e n ts t u d yi st h ef i r s tt or e p o r tt h a tt h e r ei sa
relationship between the elevated serum levels of IL-21
and IgG, (especially IgG1), in primary SS and that the
lymphocytic infiltration in the LSGs of patients with pri-
mary SS express high levels of IL-21 along with lower
levels of IL-21R. Moreover, the expression of IL-21
showed a tendency to increase as more lymphocytes
infiltrated into LSGs. Further investigations on the sys-
temic and localized effects of IL-21 in primary SS would
provide a basis for targeting this molecule for custo-
mized therapy.
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